Vertex Pharmaceuticals Inc
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 15 consecutive years on Science magazine's Top Employers list and one of Fortune’s 100 Best Companies to Work For.
Profit margin of 32.9% — that's well above average.
Current Price
$446.78
+0.64%GoodMoat Value
$284.70
36.3% overvaluedVertex Pharmaceuticals Inc (VRTX) financial data including income statement, balance sheet, and cash flow statement. This page provides a comprehensive view of Vertex Pharmaceuticals Inc's financial performance and position as a Healthcare company.
Trailing twelve-month (TTM) revenue is $12.00B. Gross profit (TTM) is $10.35B. EBITDA is $4.87B. Earnings per share (EPS) is $15.32. The P/E ratio is 28.67. Market capitalization is $113.36B.
Free cash flow (FCF) is $3.19B. FCF growth rate is 13.50%. EPS growth CAGR is 13.50%. Weighted average cost of capital (WACC) is 10.00%.
Historical revenue data covers 7 years from FY19 to FY25. Net income history spans 7 years. Free cash flow and capital expenditure data spans 7 years. GoodMoat displays interactive charts for revenue, net income, FCF vs CAPEX, and cash-to-debt ratios to help investors identify financial trends.
Use Vertex Pharmaceuticals Inc's financial data to assess the company's earnings quality, balance sheet health, and cash generation. Compare key metrics across periods to identify trends before making investment decisions with GoodMoat's valuation tools.
